Skip to main content
SpringerLink
Log in

Intensivpflichtige Hauterkrankungen

Dermatological conditions requiring intensive care

  • CME Zertifizierte Fortbildung
  • Published:
Der Hautarzt Aims and scope Submit manuscript

Zusammenfassung

Ein nicht unwesentliches Spektrum der Erkrankungen in der Dermatologie ist mit einem möglichen Aufenthalt auf einer internistischen oder chirurgischen Intensivstation assoziiert. Das frühzeitige Erkennen möglicher intensivpflichtiger Erkrankungsverläufe stellt den Dermatologen vor eine Herausforderung. Schwerpunkt dieser Übersicht sind Hauterkrankungen, die per se intensivpflichtig sind oder mit einem hohen Risiko einhergehen, intensivpflichtig zu werden. Aus dem Formenkreis schwerer Arzneimittelreaktionen werden das Stevens-Johnson-Syndrom (SJS) und die toxisch epidermale Nekrolyse (TEN), für die infektassoziierten Dermatosen das „Staphylococcal Scalded Skin Syndrome“ (SSSS) und die nekrotisierende Fasziitis präsentiert, des Weiteren werden Angioödeme thematisiert. Der klinische Verlauf der jeweiligen Erkrankung ist wegweisend für eine mögliche Intensivpflichtigkeit. Relevante Kennzeichen in Klinik und Diagnostik werden fokussiert, wichtige Differenzialdiagnosen benannt. Entsprechende Therapien werden orientierend behandelt.

Abstract

Some skin conditions may require treatment in intensive care units. The early diagnosis of life-threatening dermatoses is a considerable challenge. We review skin diseases which may require intensive care. In addition to Stevens-Johnson syndrome and toxic epidermal necrolysis, representing adverse skin reactions, we discuss staphylococcal scalded skin syndrome and necrotizing fasciitis as infection-associated dermatoses, as well as angioedema. We focus on the course of disease describing clinical presentations, diagnostics and therapeutic strategies with respect to critical medical conditions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Auquier-Dunant A, Mockenhaupt M, Naldi L et al (2002) Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 138:1019–1024

    Article  PubMed  Google Scholar 

  2. Banerji A, Sheffer AL (2009) The spectrum of chronic angioedema. Allergy Asthma Proc 30:11–16

    Article  PubMed  CAS  Google Scholar 

  3. Bastuji-Garin S, Fouchard N, Bertocchi M et al (2000) SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 115:149–153

    Article  PubMed  CAS  Google Scholar 

  4. Bastuji-Garin S, Rzany B, Stern RS et al (1993) Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 129:92–96

    Article  PubMed  CAS  Google Scholar 

  5. Beibei L, Yun C, Mengli C et al (2010) Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials. Int J Antimicrob Agents 35:3–12

    Article  PubMed  Google Scholar 

  6. Bork K, Barnstedt SE, Koch P, Traupe H (2000) Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 356:213–217

    Article  PubMed  CAS  Google Scholar 

  7. Cichon S, Martin L, Hennies HC et al (2006) Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 79:1098–1104

    Article  PubMed  CAS  Google Scholar 

  8. Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN et al (2001) Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. Aids 15:1843–1848

    Article  PubMed  CAS  Google Scholar 

  9. Faye O, Roujeau JC (2005) Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IV Ig): clinical experience to date. Drugs 65:2085–2090

    Article  PubMed  CAS  Google Scholar 

  10. Ghislain PD, Roujeau JC (2002) Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J 8:5

    PubMed  Google Scholar 

  11. Halevy S, Ghislain PD, Mockenhaupt M et al (2008) Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 58:25–32

    Article  PubMed  Google Scholar 

  12. Kahle B (2006) Vascular emergencies in dermatology. Hautarzt 57:202–206

    Article  PubMed  CAS  Google Scholar 

  13. Kardaun SH, Jonkman MF (2007) Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol 87:144–148

    Article  PubMed  CAS  Google Scholar 

  14. Kress DW (2011) Pediatric dermatology emergencies. Curr Opin Pediatr 23:403–406

    Article  PubMed  Google Scholar 

  15. Kroshinsky D, Alloo A, Rothschild B et al (2012) Necrotizing Sweet syndrome: a new variant of neutrophilic dermatosis mimicking necrotizing fasciitis. J Am Acad Dermatol [Epub ahead of print]

  16. Lancerotto L, Tocco I, Salmaso R et al (2012) Necrotizing fasciitis: classification, diagnosis, and management. J Trauma Acute Care Surg 72:560–566

    PubMed  Google Scholar 

  17. Levi N, Bastuji-Garin S, Mockenhaupt M et al (2009) Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics 123:e297–304

    Article  PubMed  Google Scholar 

  18. Longhurst HJ, Bork K (2006) Hereditary angioedema: causes, manifestations and treatment. Br J Hosp Med (Lond) 67:654–657

    Google Scholar 

  19. Maurer M, Magerl M (2010) Hereditary angioedema: an update on available therapeutic options. J Dtsch Dermatol Ges 8:663–672

    PubMed  Google Scholar 

  20. Mockenhaupt M (2011) The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol 7:803–813 (quiz 814–805)

    Article  PubMed  Google Scholar 

  21. Mockenhaupt M (2009) Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. J Dtsch Dermatol Ges 7:142–160 (quiz 161–142)

    PubMed  Google Scholar 

  22. Mockenhaupt M, Idzko M, Grosber M et al (2005) Epidemiology of staphylococcal scalded skin syndrome in Germany. J Invest Dermatol 124:700–703

    Article  PubMed  CAS  Google Scholar 

  23. Mockenhaupt M, Viboud C, Dunant A et al (2008) Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 128:35–44

    Article  PubMed  CAS  Google Scholar 

  24. Patel GK, Finlay AY (2003) Staphylococcal scalded skin syndrome: diagnosis and management. Am J Clin Dermatol 4:165–175

    Article  PubMed  Google Scholar 

  25. Pitambe HV, Schulz EJ (2005) Life-threatening dermatoses due to metabolic and endocrine disorders. Clin Dermatol 23:258–266

    Article  PubMed  Google Scholar 

  26. Sassolas B, Haddad C, Mockenhaupt M et al (2010) ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther 88:60–68

    Article  PubMed  CAS  Google Scholar 

  27. Schneck J, Fagot JP, Sekula P et al (2008) Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 58:33–40

    Article  PubMed  Google Scholar 

  28. Semple D, Keogh J, Forni L, Venn R (2005) Clinical review: vasculitis on the intensive care unit – part 2: treatment and prognosis. Crit Care 9:193–197

    Article  PubMed  Google Scholar 

  29. Stander HF (2012) Medical emergencies in daily dermatological practice. Hautarzt 63:329–340

    Article  PubMed  CAS  Google Scholar 

  30. Stone SP, Buescher LS (2005) Life-threatening paraneoplastic cutaneous syndromes. Clin Dermatol 23:301–306

    Article  PubMed  Google Scholar 

  31. Usatine RP, Sandy N (2010) Dermatologic emergencies. Am Fam Physician 82:773–780

    PubMed  Google Scholar 

  32. Valeyrie-Allanore L, Wolkenstein P, Brochard L et al (2010) Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 163:847–853

    Article  PubMed  CAS  Google Scholar 

  33. Viard I, Wehrli P, Bullani R et al (1998) Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282:490–493 (New York, NY)

    Article  PubMed  CAS  Google Scholar 

  34. Wolkenstein P, Latarjet J, Roujeau JC et al (1998) Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 352:1586–1589

    Article  PubMed  CAS  Google Scholar 

  35. Wüthrich B (2012) Angioödeme, selten allergisch bedingt. 1. Teil: Klassifikation, Pathophysiologie, Diagnostik. Schweiz Med Forum 12:138–143

    Google Scholar 

  36. Ziemer M, Wiesend CL, Vetter R et al (2007) Cutaneous adverse reactions to valdecoxib distinct from Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 143:711–716

    Article  PubMed  CAS  Google Scholar 

  37. Zuberbier T, Asero R, Bindslev-Jensen C et al (2009) EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy 64:1417–1426

    Article  PubMed  CAS  Google Scholar 

Download references

Danksagung

Wir bedanken uns bei Dr. Martin Kaatz für die konstruktive Durchsicht des Manuskripts.

Interessenkonflikt

Der korrespondierende Autor gibt für sich und seinen Koautor an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Abt. für Hämatologie/Onkologie, Medizinische Universitätsklinik Freiburg, Hugstetter Str. 55, 79106, Freiburg, Deutschland

    C. Marks & R. Marks

Authors
  1. C. Marks
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Marks
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Marks.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marks, C., Marks, R. Intensivpflichtige Hauterkrankungen. Hautarzt 63, 727–738 (2012). https://doi.org/10.1007/s00105-012-2421-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-012-2421-0

Schlüsselwörter

Keywords

Search

Navigation